Abstract
Fondaparinux sodium (Arixtra®) is a synthetic, sulfated pentasaccharide, selective factor Xa inhibitor that is indicated in Europe for preventing thrombus formation in patients with acute coronary syndromes (ACS; the focus of this review), including those with ST-segment elevation myocardial infarction (STEMI), non-STEMI (NSTEMI), or unstable angina.
The large (n = 20 078), well designed OASIS-5 trial showed that subcutaneous fondaparinux 2.5 mg/day for ≤8 days was noninferior to subcutaneous enoxaparin 1 mg/kg twice daily (once daily in those with renal dysfunction) in reducing death or ischemic events at 9 days and the efficacy was maintained for up to 6 months (study end) in patients with unstable angina or NSTEMI. During this time, major bleeding occurred in fewer fondaparinux than enoxaparin recipients, resulting in a benefit: risk balance favoring fondaparinux. The incidence of death or reinfarction at 30 days was significantly lower in recipients of subcutaneous fondaparinux 2.5 mg/day than in those who received usual care (including unfractionated heparin treatment as indicated) in patients with STEMI in the large (n > 12 000) OASIS-6 trial. There were no differences in the incidence of major bleeding between these groups, resulting in a benefit: risk balance favoring fondaparinux.
The specificity and selectivity of fondaparinux, combined with its long half-life and 100% bioavailability, allows once-daily anticoagulation without the need for monitoring activated clotting time. Subcutaneous fondaparinux was noninferior to enoxaparin treatment in patients with unstable angina or NSTEMI, and was more effective than usual care in those with STEMI. Fondaparinux has a favorable tolerability profile, particularly with regard to the risk of major bleeding, and limited data suggest that it is more cost effective than enoxaparin in the short term. Thus, overall, clinical evidence suggests that fondaparinux has a valuable place in the treatment of patients with ACS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Blick SKA, Orman JS, Wagstaff AJ, et al. Fondaparinux sodium: a review of its use in the management of acute coronary syndromes. Am J Cardiovasc Drugs 2008; 8(2): 113–25
Petitou M, Duchaussoy P, Jaurand G, et al. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentassarcharide. J Med Chem 1997; 40: 1600–7
Lormeau JC, Herault JP, Gaich C, et al. Determination of the antifactor Xa activity of the synthetic pentasaccharide SR 9017A/ORG 31540 and of two structural analogues. Thromb Res 1997; 85(1): 67–75
Bauer KA. New pentassaccharides for prophylaxis of deep vein thrombosis. Chest 2003; 124(6): 364S–70S
Olson ST, Bjork I, Sheffert R, et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin proteinase reactions. J Biol Chem 1992 Jun; 267(18): 12528–38
Robinson DM, Wellington K. Fondaparinux sodium: a review of its use in the treatment of acute venous thromboembolism. Am J Cardiovasc Drugs 2005; 5(5): 335–46
European Medicines Agency. Fondaparinux sodium: Arixtra™ 1.5mg/0.3mL solution for injection; summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/arixtra/H-403-PI-en.pdf [Accessed 2008 Mar 28]
Boneu B, Necciari J, Cariou R, et al. Pharmacokinteics and tolerance of the natural pentasaccharide (SR90107/ORG31540) with high affinity to antithrombin III in man. Thromb Haemost 1995; 74(6): 1468–73
Bijsterveld MD, Moons AH, Boekholdt M, et al. Ability of recombinant factor Vila to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002 Nov 12; 106: 2550–4
US Food and Drug Administration. Fondaparinux Sodium: Atrixtra® injection prescribing information [online]. Available from URL: http://www.fda.gov/cder/foi/label/2005/021354s010LbL.pdf [Accessed 2008 Mar 28]
Donat F, Duret JP, Santoni A. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002; 41Suppl. 2: 1–9
Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006 Apr 6; 354(14): 1464–76
Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006 Apr 5; 295(13): 1519–30
Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007 Oct 30; 50(18): 1742–51
Genth-Zotz S, Rupprecht H-J, Mehta SR, et al. Early benefit of fondaparinux in patients with non-ST elevation acute coronary syndromes: a secondary analysis of the OASIS-5 trial [abstract no. V1744]. 73rd Annual Meeting of the German Society for Cardiology, Heart and Circulation Research; 2007 Apr 12–14; Mannheim
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Blick, S.K., Orman, J.S., Wagstaff, A.J. et al. Spotlight on Fondaparinux Sodium in Acute Coronary Syndromes. BioDrugs 22, 413–415 (2008). https://doi.org/10.2165/0063030-200822060-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/0063030-200822060-00007